Jalal K. Ghali
Jalal K Ghali

Department of Medicine
Mercer University School of Medicine




Damascus University Medical School



Dr. Ghali is Professor of Medicine at Mercer University.  He is the Associate Chair for Clinical Research and Chief of Cardiology.  He received his MD degree from Damascus University in Syria. He is board certified in internal medicine and cardiovascular medicine. As principal investigator, Dr. Ghali has conducted over 200 clinical trials predominantly in heart failure and has contributed to the medical literature more than 200 publications, predominantly in the field of heart failure. He currently serves on the editorial board of the American Heart Journal, Journal of Cardiac Failure, European Journal of Heart Failure, JACC:  Heart Failure, Current Cardiology Review, Open Heart Failure Journal, World Journal of Cardiology, American Journal of Cardiovascular Disease, World Journal of Cardiovascular Diseases, Journal of Cardiology and Vascular Medicine, Advances in Medicine, Scholarena Journal of Cardiology, Journal of Experimental Cardiology and Research, International Journal of Vascular Surgery and Medicine, International Archives of Translational Medicine, International Journal of Clinical Cardiology, Roger Publishing Group Journal of Cardiology, Clinical Research and Trials, Emergency Medicine: Open Access and SM Journal of Cardiology and Cardiovascular Diseases. Editor-in-Chief for Emergency Medicine: Open Access and Secondary Editor-in-Chief for Clinical Research and Trials. He has served as a member of several steering committees, adjudication committees and data and safety monitoring boards in various heart failure trials. He came to Mercer from Detroit where he held the positions of Director of Cardiovascular clinical trials and the heart failure program at the Cardiovascular Institute, Detroit Medical Center, Chief of Cardiology, Detroit Receiving Hospital and Associate Chair for Research at Wayne State University.

Research Interest


Professional Activities:

  1. Investigation of Current Clinical Patterns and Outcome of Patients with Heart Failure – UNITE HF Heart Failure Database (UNITE-HF – United Investigators to Evaluate Heart Failure), University of North Carolina.  Member, 2000-
  2. SPORTIF V:  Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H376/95 Compared With Dose-Adjusted Warfarin (Coumadin®) in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation. AstraZeneca Pharmaceuticals.  Member, 2001-
  3. HF-ACTION for Heart Failure and AControl Trial Investigating Outcomes of Exercise TraiNing.  Duke Clinical Research Institute Member, 2002-
  4. STAMINA-HFP REGISTRY STUDY (Study of AneMia IN A Heart Failure Population).  A Multi-Center, Prospective, Observational Heart Failure Registry Study.  University of North Carolina/Amgen.  Member, 2002-
  5. MD-CHF:  A Phase IV, Multicenter, Double-Blind, Randomized, Parallel Group, Dose-Response Study to Assess the Effect of Extended Release Metoprolol Succinate (Toprol-XL®) on Cardiac Remodeling in Symptomatic Chronic Heart Failure Patients with Left Ventricular Dysfunction.  AstraZeneca.  Member, 2003-
  6. A Phase I-II, Dose Escalating Study Evaluating the Safety and Tolerability of PST 2744 and Specific Effects on Electrocardiographic and Hemodynamic Parameters in Patients with Chronic Heart Failure and Reduced Systolic Function.  The “STEP-CHF” Study.  (ST 03-501).  Sigma-Tau Research, Inc.



  1. Cooper R, Sempos C, Ghali J, Ferlinz J. High Density Lipoprotein-Cholesterol and Angiographic Artery Disease in Blacks. Am Heart J 1985:110:1006-11.
  2. Ghali J, Shanes J.A Review of Dilated Cardiomyopathy. ComprehensiveTherapy 1987;13(8):46-56.
  3. Shanes J, Ghali J. Endomyocardial Biopsy Results. Cardiology Board Review 1987;4(9):112-21
  4. Shanes J, Ghali J, Billingham M, Ferrans V, Fenoglio J, Edwards W, Tsai C, Saffitz J, Isner J, Furner S, Subramanian R.  Interobserver Variability in the Pathologic Diagnosis of Endomyocardial Biopsy Results. Circulation 1987:74(2):401-5.
  5. Simmons B, Castaner A, Santhanam V, Ghali J, Silverman N, Goldfaden D, Levitsky S, Cooper R, Ferlinz J.  Outcome of Coronary Artery Bypass Grafting in Black Persons. Am J Cardiol 1987;59:547-51.
  6. Lang RM, Borow KM, Neumann A, Newmann A, Carroll JD, Weinert L, Murphy MB, Ghali J, Rajfer SI. Role of the Beta2 Adrenoceptor in Mediating Positive Inotropic Activity in the Failing Heart and Its Relation to the Hemodynamic Actions of Dopexamine Hydrochloride. Am J Cardiol 1988;62:46C-52C.
  7. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating Factors Leading to Decompensation of Heart Failure. Arch Intern Med 1988;148:2013-6.
  8. Shanes J, Wolfkiel C, Ghali J, Direnfeldt B, Kondos G, Bauman J. Acute Hemodynamic Effects of Pindolol and Propranolol in Patients With Dilated Cardiomyopathy: Relevance of Intrinsic Sympathomimetic Activity. Am Heart J 1988;116:1268-75.
  9. Ghali JK, Saksena F, Sanathanam V, Hu I, Perkins J.  Echocardiographic Findings in a Malignant Fibrosis Histiocytoma of the Heart. J Cardiovasc Ultrasound 1988;7:353-58.
  10. Ghali J, Shanes. Beta-Blockade in Heart Failure. An Optimistic View. Cardiovasc Perspect 1990;5(1):1-3.
  11. Cooper RS, Simmons BE, Castaner A, Santhanam V, Ghali J, Mar M. Left Ventricular Hypertrophy is Associated With Worse Survival Independent of Ventricular Function and Number of Coronary Arteries Severely Narrowed. Am J Cardiol 1990;65:441-45.
  12. Ghali JK, Cooper R, Ford E.  Trends in Hospitalization Rates for Heart Failure in the United States,     1973-1986: Evidence for Increasing Population Prevalence. Arch Int Med 1990;150:769-73.
  13. Mirvis DM, Insel J, Boland MJ, Cinquegrani MP, Ghali JK, Rubin SA, Shanes J, DeSilva J, Whalen JJ. Chronic Therapy for Congestive Heart Failure With Benzepril HCI, a New Angiotensin Coverting   Enzyme Inhibitor. Am J Medical Sciences 1990;300 (6):354-60.
  14. Ghali JK, Kadakia S. Cooper RS, Liao Y.  The Impact of Left Ventricular Hypertrophy on Ventricular Arrhythmias in the Absence of Coronary Artery Disease. J Am Coll Cardiol 1990;17:1277-82.
  15. Stroke Prevention in Atrial Fibrillation Study Group Investigators: Preliminary Report of the Stroke Prevention in Atrial Fibrillation Study. N Eng J Med 1990;322:863-868.
  16. Studies of Left Ventricular Dysfunction (SOLVD)-Rationale, Design and Methods: Two Trials That Evaluate the Effect of Enalapril in Patients With Reduced Ejection Fraction. The SOLVD Investigators.  Am J Cardiol 1990;66:315-322.
  17. Stroke Prevention in Atrial Fibrillation Investigators. Design of a Multicenter Randomized Trial for the Stroke Prevention in Atrial Fibrillation Study. Stroke 1990;21:538-545.
  18. Cooper RS, Ghali JK, Simmons BE, Castaner A.  Elevated Pulmonary Artery Pressure. An Independent Predictor of Mortality. Chest 1991;99:112-20.
  19. Ghali JK, Kadakia S, Cooper RS, Liao Y.  Bedside Diagnosis of Preserved Versus Impaired Left Ventricular Systolic Function in Heart Failure. Am J Cardiol 1991;67:1002-6. 
  20. Hood WB Jr., Youngblood M, Ghali JK, Reid M, Rogers WJ, Dowe D, Teo KK, Lejemtel TH. Studies of Left Ventricular Dysfunction (SOLVD). Initial Blood Pressure Response to Enalapril in Hospitalized Patients. Am J Cardiol 1991;1465-8.
  21. Ghali JK. Clinical Signs Assess Left Ventricular Dysfunction in Heart Failure at Bedside. Today in Medicine (August 1991).
  22. Ghali JK. Should Cardiovascular Diseases be a Health Priority for Developing Countries? A Brief Overview of the Mortality Data. Eth and Dis 1991;1:295-9.
  23. The SOLVD Investigators. Effect of Enalapril on Survival in Patients With Reduced Left Ventricular Ejection Fraction and Congestive Heart Failure. N Engl J Med 1991;325:293-302.
  24. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study Final Results. Circulation 1991;84:527-539.
  25. Ghali JK, Kadakia S, Cooper RS, Liao Y. Hypertensive Left Ventricular Hypertrophy and Ventricular Arrhythmias. Cardiology Board Review 1992;9:20-24
  26. Ghali JK, Kadakia S, Bhatt A, Cooper R, Liao Y.  Survival of Heart Failure Patients With Preserved Versus Impaired Systolic Function: The Prognostic Implication of Blood Pressure. Am Heart J 1992;123: 993-7.
  27. Ghali JK, Liao Y, Cooper RS, Cao G. Changes in Pulmonary Hemodynamics with Aging in a Predominantly Hypertensive Population. Am J Cardiol 1992;70:367-70.
  28. Bangdiwala SI, Weiner DH, Bourassa MG, Friesinger GC, Ghali JK, Yusuf S.  Studies of Left Ventricular Dysfunction (SOLVD) Registry: Rationale, Design, Methods and Description of Baseline Characteristics.  Am J Cardiol 1992;70:347-53.
  29. Liao Y, Cooper RS, Ghali JK, Szocka A. Survival Rates With Coronary Artery Disease for Black Women Compared With Black Men. JAMA 1992;268:1867-71.
  30. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The Prognostic Role of Left Ventricular Hypertrophy in Patients With or Without Coronary Artery Disease. Ann Intern Med 1992;117:831-6.
  31. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of Thromboembolism in Atrial   Fibrillation:I. Clinical Features of Patients at Risk. Ann Intern Med 1992;116:1-5.
  32. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of Thromboembolism in Atrial Fibrillation:II. Echocardiographic Features of Patients at Risk. Ann Intern Med 1992;116:6-12.
  33. Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients With Reduced Left Ventricular Ejection Fractions. N Engl J Med 1992;327:685-691.
  34. Ghali JK, Kadakia S, Bhatt A, Cooper RS, Liao Y. Survival of Heart Failure Patients With Preserved Versus Impaired Systolic Function. Cardiology Board Review 1993;10:36-44
  35. Ghali JK, Cooper RS, Kowatly I, Liao Y. Delay Between Onset of Chest Pain and Arrival to the Coronary Care Unit Among Minority and Disadvantaged Patients. J Natl Med Assoc 1993;85:180-84.
  36. Liao Y, Cooper RS, Ghali JK, Lansky D, Cao G, Lee J. Sex Differences in the Impact of Coexistent Diabetes on Survival in Patients With Coronary Heart Disease. Diabetes Care 1993;16:5:708-13.
  37. Van TB, Halldorsson A, Bausum RW, Ratts TE, Mosley LE, Eggerstadt JM, Hanley HG. Retrieval of a Distal Pulmonary Artery Vegetative Embolus Under Transesophageal Echocardiographic Guidance. Echocardiography: A J CV Untra & Allied Tech 1993;10:5:489-95.
  38. Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, Kirlin P, Greenburg B, Quinones MA, Yusuf S, For the SOLVD Investigators. Comparative Neurohormonal Responses in Patients With Preserved and Impaired Left Ventricular Ejection Fraction: Results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. J Am Coll Cardiol 1993;22:[Supp A]:146A-53A.
  39. Bourassa MG, Gurné O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, Johnstone DE, Yusuf S, for the SOLVD Investigators. Natural History and Patterns of Current Practice in Heart Failure.  J Am Coll Cardiol 1993; 22:4:14A-19A.
  40. Saksena FB, Ghali JK, Chomka EV, Brundage BL. The Diagnosis of Papillary Computed Tomography.J Cardiov Diag and Proc 1993;11:2:135-40.
  41. Ghali JK. Ischemic Heart Failure. J La State Med Soc 1995;5:147:202-7
  42. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The Relative Effects of Left Ventricular Hypertrophy, Coronary Artery Disease, and Ventricular Dysfunction on Survival Among Black Adults.  JAMA 1995;273:20:1592-7.
  43. Intracoronary  t-PA Registry Investigators. Clinical Experience with Intracoronary Tissue Plasminogen Activator: Results of a Multicenter Registry. Cathet & Cardiovas Diagn 1995;34: 196-201.
  44. Shindley DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC, for the SOLVD Investigators. Diabetes Mellitus, a Predictor of Morbidity and Mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol1996; 77:1017-20.
  45. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheiner JH, Meese RB, Old WD, Willis PW, Cropp AB, Anderson Sa, DeMets DL, for the Prospective Randomized Amlodipine Survival Evaluation (PRAISE) Study Group. Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure. N Engl J Med 1996;335:15:1107-14.
  46. Liendo C, Ghali JK, Graves SW. A New Interference in Some Digoxin Assays: Anti-Murine Heterophilic Antibiodies. Clin Pharmacol Ther 1996;60:593-8.
  47. Ghali JK, Liao Y, Cooper RS. Left Ventricular Hypertrophy in Blacks. Urban Cardio 1997;4:2:8-15
  48. Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali JK. Prediction of Mortality Risk by Different Methods of Indexing for Left Ventricular Mass. J Am Coll Cardiol 1997;29:641-7.
  49. Mohler ER, Sorensen LC, Ghali JK, Schocken DD, Willis PW, Bowers JA, Cropp AB, Pressler ML. Role of Cytokines in the Mechanism of Action of Amlodipine: The PRAISE Heart Failure Trial. J Am Coll Cardiol 1997;30:35-41.
  50. Ghali JK, Liao Y, Cooper RS. Left Ventricular Hypertrophy in the Elderly. Am J Geriatr Cardiol 1997;6(6):38-49.
  51. Ghali JK, Giles T, Gonzales M, Horswell R, Kumar S, LeJeune A, Livaudais GF, Sarkar IC. Patterns of Physician User of Angiotensin Converting Enzyme Inhibitors in the Inpatient Treatment of Congestive Heart Failure. J La State Med Soc 1997;149:474-83.
  52. Randomized Trial of Losartan Versus Captopril in Patients Over 65 With Heart Failure (Evaluation of  Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
  53. Ghali JK, Liao Y, Cooper RS, Influence of Left Ventricular Geometric Patterns on Prognosis in Patients With or Without Coronary Artery Disease. J Am Coll Cardiol 1998;31:7:1635-40.
  54. Ghali JK, Mosley L, Danzell J, Eaves B. Heart Failure in Women. J La State Med Soc 1998;150:85-91
  55. Ghali JK, Mosley L, Abreo F, Abreo K. 63-Year Old Woman With Heart Failure. J La State Med Soc 1998;150:350-54
  56. Inhibition of Platelet Glycoprotein IIb/IIIa With Eptifibatide in Patients With Acute Coronary Syndromes.  The PURSUIT Trial Investigators. N Engl J Med 1998;339:436-443.
  57. Effect of Metoprolol CR/XL in Chronic Heart Failure: Metroprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. Lancet 1999;353:2001-2007.
  58. Levine BT, Bernik PJLM, Caspi A, Elkayam U, Geltman EM, Greenburg B, Mckenna WJ, Ghali JK, Giles TD, Marmor A, Reisin LH, Ammon S, Lindberg E. Effect of Mibefradil, A T-Type Calcium Channel Blocker, on Morbidity and Mortality in Moderate to Severe Congestive Heart Failure. The MACH-1 Study. Circulation 2000;101:758-64.
  59. Comparison of Sibrafiban with Aspirin for Prevention of Cardiovascular Events After Acute Coronary Syndromes: A Randomized Trial.  The SYMPHONY Investigators. Lancet 2000; 355:337-345.
  60. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, Ghali JK, Liebson PR. Heart Failure With a Normal Ejection Fraction. Is Measurement of Diastolic Function Necessary to Make the Diagnosis of Diastolic Heart Failure? Circulation 2001;104:7:779-82.
  61. Burger AJ, Elkayam U, Neibaur MT, Haught H, Ghali, JK, Horton DP, Aronson D.  Comparison of the Occurrence of Ventricular Arrhythmias in Patients with Acutely Decompensated Congestive Heart Failure Receiving Dobutamine versus Nesiritide Therapy.  Am J Cardiol 2001;88:35-39.
  62. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA.  Acute Hemodynamic Effects of Conivaptan, a Dual V1Aand V2Vasopressin Receptor Antagonist, in Patients with Advanced Heart Failure. Circulation 2001;104:20:2417-2423.
  63. Liao Y, Ghali JK, Berzins I, Cooper RS.  Coronary Angiographic Findings in African-American and White Patients From a Single Institution.  J Nat Med Assoc 2001;93:12:465-474.
  64. Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes.  Second SYMPHONY Investigators. Circulation 2001;103:1727-1733.
  65. A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure. N Engl J Med 2001;344:1659-1667.
  66. Effects of Clopidogrel in Addition to Aspirin in Patients With Acute Coronary Syndromes Without ST-Segment Elevation.  CURE Study Investigators. N Engl J Med 2001;345:7:494-502.
  67. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC.  Treating Female Heart Failure Patients With Metoprolol CR/XL. Cardiology Review 2002;19:29-32
  68. Wikstrand J, Ghali JK, Goldstein S.  Consistency of β-blocker effect across various subgroups with heart failure.  Postgraduate Medicine November2002;16-23
  69. Silver M, Horton DP, Ghali JK, Elkayam U.  Effect of Nesiritide Versus Dobutamine on Short-Term Outcomes in the Treatment of Patients with Acutely Decompensated Heart Failure. J Am Coll Cardiol;2002;39:798-803.
  70. Ghali JK, Piña IL, Gottlieb SS, Deedwania PC, Wikstrand JC.  Metoprolol CR/XL in Female Patients with Heart Failure. Analysis of the Experience in MERIT-HF (Metoprolol Controlled-Release Randomized Intervention Trial in Heart Failure). Circulation 2002;105:1585-91.
  71. Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, Koren M, Dinerman J, Silver M, Cheng ML, Elkayam U.  Effect of Nesiritide (B-type natariuretic peptide) and Dobutamine on Ventricular Arrhythmias in the Treatment of Patients with Acutely Decompensated Congestive Heart Failure:  The PRECEDENT Study.  Am Heart J 2002;144:1102-8.
  72. Wikstrand J, Wedel H, Ghali J, Deedwania P, Fagerberg B, Goldstein S, Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F.  How Should Subgroup Analyses Affect Clinical Practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart  Failure (MERIT-HF).  Cardiac Electrophysiology Review 2003;7:264-275
  73. Wijeysundera HC, Hansen MS, Stanton E, Cropp AS, Hall C, Dhalla NS, Ghali J, Rouleau JL;  PRAISE II Investigators.  Neurohormones And Oxidative Stress In Non Ischemic Cardiomyopathy: Relationship to Survival and the Effect of Treatment with Amlodipine.  Am Heart J 2003;146:291-7.
  74. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR, for the BEST Investigators.  The Effect of Diabetes on Outcomes of Patients with Advanced Heart Failure in the BEST Trial.  J Am Coll Cardiol 2003;42:914-22.
  75. Lindenfeld J, Ghali JK, Krause-Steinrauf HJ, Khan S, Adams K, Goldman S, Peberdy MA, Yancy C, Thaneemit-Chen S, Larsen RL, Young J, Lowes B, Rosenberg YD, and the BEST Investigators.  Hormone Replacement Therapy is Associated with Improved Survival in Women with Advanced Heart Failure.J Am Coll Cardiol 2003;42 (7):1238-45.
  76. Janosi A, Ghali JK, Herlitz J, Czuriga I, Klibaner M, Wikstrand J, Hjalmarson A and MERIT-HF Study Group.  Metoprolol CR/XL in Postmyocardial Infarction Patients with Chronic Heart Failure: Experiences from MERIT-HF.  Am Heart J 2003;146: (4):721-28.
  77. Ghali JK, Krause-Steinrauf HJ, Adams, Jr. KF, Khan SS, Rosenberg YD, Yancy, Jr. CW, Young JB, Goldman S, Peberdy MA, Lindenfeld J. Gender Differences in Advanced Heart Failure: Insights from the BEST Study.  J Am Coll Cardiol 2003;42:2128-2134.
  78. Gheorghiade M, Gattis WA, O’Connor CM, Adams, Jr, KF, Elkayam U, Barbagelata A, Ghali, JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C.  Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure. A Randomized Controlled Trial.   JAMA 2004;291:1963-1971.
  79. Ghali JK. Sex-related Differences in Heart Failure and Beta-Blockers. Heart Failure Reviews2004;9: 149-159
  80. Deedwania PC, Gottlieb S, Ghali JK, Waagstein F, Wikstrand JCM.  Efficacy, Safety and Tolerability of ß-adrenergic BlocKade with Metoprolol CR/XL in Elderly Patients with Heart Failure.  Eur Heart J 2004;25:15:1300-1309.
  81. Ghali JK, Dunselman P, Waagstein F, Goldstein S, Gottlieb SS, Deedwania PC, Wikstrand JC.  Consistency of the Beneficial Effect of Metoprolol Succinate Extended Release Across a Wide Range   Dose of Angiotensin-Converting Enzyme Inhibitors and Digitalis.  J Card Fail 2004;10:6:452-459.
  82. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and other combination in high-risk patients:  The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.  The ONTARGET/TRANSCEND Investigators Am Heart J 2004:148:52-61
  83. The SYNERGY Trial Investigators.  Enoxaparin vs Unfractionated Heparin in High-Risk Patients with Non-ST-Segment Elevation Acute Coronary Syndromes Managed with an Intended Early Invasive Strategy.  JAMA 2004;292:45-54.
  84. Ghali JK.  Beta Blockers in Selected Heart Failure Populations.  Current Heart Failure Reports 2005, 2:100-105
  85. Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, Wojciechowski D, Ansmite B, Skards J, Laks T, Henry D, Packer M, Pfeffer MA; OVERTURE Investigators. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Investigators. Am Heart J 2005;150(2):257-262.
  86. Deedwania PC, Giles TD, Klibaner M, Ghali, JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J. Efficacy, Safety and Tolerability of Metoprolol CR/XL in Patients with Diabetes and Chronic Heart Failure: Experiences from MERIT-HF.  Am Heart J 2005;149:159-167.
  87. Krum H, Haas SJ, Eichhorn E, Ghali JK, Gilbert E, Lechat P, Packer M, Roecker E, Verkenne P, Wedel H, Wikstrand J.  Prognostic Benefit of Beta-Blockers in Patients not Receiving ACE-Inhibitors.  Euro Heart Journal 2005;26:2154-2158.
  88. Solomon SD, Hicham S, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica W, Khrakovskaya M, Arnold JMO, Schwartz Y, Velazques EJ, Califf RM, McMurray JV, Pfeffer MA.  Changes in Ventricular Size and Function in Patients Treated with Valsartan, Captopril, or Both After Myocardial Infarction.  Circulation.2005; 111:3411-3419.
  89. Carson P, Anand I, O’Connor C, Jaski B, Steinberg J, Lwin A, Lindenfeld J, Ghali J, Barnet JH, Feldman AM, Bristow MR.  Mode of Death in Advanced Heart Failure.  J Am Coll Cardiol 2005;46(12):2329-2334.
  90. Angus CD, Linde-Zwirble WT, Tam SW, Ghali JK, Sabolinski ML, Villagra VG, Winkelmayer WC, Worcel M.  Circulation 2005;112;3745-3753.
  91. Eichhorn E, Metra M, Abraham W, Amuchastegui M, Binkley P, Bohm M, Deedwania P, DeMarco T, Elkayam U, Ford I, Ghali J, Guzman L, Klapholz M, Kuschnir E, Liu P, Perna E, Perrone S, Mareev V, Yao L, Soler-Soler J, Komajda M, Poole-Wilson P, Tendera M, Dargie H, Swedberg K, Lowes B, Bristow M.  ESSENTIAL – The studies of oral enoximone therapy in advanced heart failure. J Card Fail 2005;11(9):721.
  92. Ghali JK, Kore MJ, Taylor JR, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N. Efficacy and Safety of Oral Conivaptan: A V1A/V2 Vasopressin Receptor Antagonist, Assessed in a Randomized, Placebo-controlled Trial in Patients with Euvolemic or Hypervolemic Hyponatremia. J Clin Endocrinol Metab 2006; 91(6):2145-2152.
  93. Thune JJ, Kober L, Pfeffer MA, Skali H, Anavekar NS, Bourgoun M, Ghali JK, Arnold JM, Velazquez, EJ, Solomon SD. Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study.J Am Soc Echocardiogr 2006;19(12):1462-1465.
  94. Lindenfeld J, Feldman AM, Saxon L, Boehmer J, Carson P, Ghali JK, Anand I, Singh S, Steinber JS, Jaski B, DeMarco T, Mann D, Yong P, Galle E, Ecklund R, Bristow M. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007;115(2):204-212.
  95. Ghali JK, Smith WB, Torre-Amione G, Haynos W, Rayburn BK, Amato A, Zhang D. Cowart D, Valentino G, Carminati P, Gheorghiade M. A phase 1-2 dose escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Am J Cardiol 2007;99(2A):S47-56.
  96. Amigoni M, Meris A, Thune JJ, Mangalat D, Skali H, Bourgoum M, Warnica JW, Barvik S, Arnold JM, Velazquez EJ, Van de Werf, Ghali JK, Mc Murray JJ, Kober L, Pfeffer MA, Solomon SD. 196 in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both; prognostic significance and relation to ventricular size and function. Eur Heart J 2007;28(3):326-33.
  97. Orlov MV, Ghali JK, Araghi-NiKnam M, Sherfesee L, Sahr D, Hettrick DA. Asymptomatic atrial fibrillation in pacemaker recipients: incidence, progression, and determinants based on the atrial high rate trial. Pacing Clin Electrophysiol. 2007;30(3):404-411.
  98. Ghali JK, Orlov MV, Araghi-Niknam M, Sherfesee L, Hettrick DA. The Influence of Symptoms and Device Detected Atrial Tachyarrhythmias on Medical Management: Insights from A-Hirate. Pacing Clin Electrophysiol. 2007;30:850-857.
  99. Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic Potential of Vasopressin Receptor Antagonists. Drugs. 2007;67(6):847-858
  100. Ali F, Raufi MA, Washington B, Ghali JK. Conivaptan: A Dual Vasopressin Receptor V1a/V2 Antagonist. Cardiovascular Drug Reviews. 2007;25(3):261-279
  101. Insull Jr. W, Ghali JK, Hassman DR, Ycas JW, Gandhi SK, et al. Achieving Low-Density Lipoprotein Cholesterol Goals in High-Risk Patients in Managed Care: Comparison on Rosuvastatin, Atorvastatin and Simvastatin in the SOLAR Trial. Mayo Clin Proc. 2007;82:543-550.
  102. Colucci WS, Kolias TJ, Adms KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B. Klibaner MI, Kukin ML, Sugg: on behalf of the REVERT Study Group. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction. The Reversal of Ventricular Remodeling with Toprol-XL (REVERT) Trial. Circulation. 2007;116:49-56.
  103. Yancy CW, Ghali JK, Braman VM, Sabolinski ML, Worcel M, Archambault WT, Franciosa JA. Evidence for the Continued Safety and Tolerability of Fixed-Dose Isosorbide Dinitrate/Hydralazine in Patients With Chronic Heart Failure (the Extension to African-American Heart Failure Trial). Am J Cardiol. 2007;100:684-689.
  104. Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN. Effect of angiotensine converting enzyme inhibitor or beta blocker use on the benefit of fixed-dose combined isosorbide dinitytrate/hydralazine in the African-American Heart Failure Trial. Am J Cardiovasc Drugs. 2007;7(5):373-380.
  105. Ghali JK, Boehmer J, Feldman AM, Saxon LA, Marco T, Carson P, Yong P, Galle EG, Leigh J, Ecklund FL, Bristow MR. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail. 2007;13:769-73.
  106. Ghali JK, Lindenfeld J. Sex differences in response to chronic heart failure therapies. Expert Rev Cardiov Ther 2008;6(4):555-65.
  107. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman M, Sun K, Knusel B, Armstrong P. The impact of darbepoetin alfa on exercise tolerance in patients with heart failure and anemia: A randomized, double-blind, placebo-controlled study. Circulation. 2008;117:526-535.
  108. De Marco T, Wolfel E, Feldman AM, Lowes B, Higginbottom MB, Ghali JK, Wagoner LKirlin PC, Kennett JD, Goel S, Saxon, LA, Boehmer JP, Mann D, Galle E, Ecklund F,          Yong P, Bristow MR.Impact of cardiac resynchronization therapy on exercise performance,           functional capacity and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J Card Fail. 2008;14:9-18.
  109. Faraz HA, Zafar SF, Ghali JK.Anemia and the potential role of erythropoiesis-stimulating agents in heart failure.Curr Heart Fail Rep. 2008 Jun;5(2):83-90
  110. Anavekar NS, Skali H, Bourgoun M, Ghali JK, Kober L, Maggioni AP, McMurray JJ, Velazquez E, Califf R, Pfeffer MA, Solomon SD. Usefulness of Right Ventricular Fractional Area Change to Predict Death, Heart Failure, and Stroke FollowingMyocardial Infarction (from the VALIANT ECHO Study). Am J Cardiol. 2008;101:607-612.
  111. Ghali JK. Mechanisms, Risks and New Treatment Options for Hyponatremia. Cardiology. 2008;111:147-157.
  112. Verma A, Meris A, SKali H, Ghali JK, Arnold JMO, Bourgoun M, Velazquez EJ, McMurray JJV, Kober L, Pfeffer MA, Califf RM, Solomon SD. Prognostic Implications of left Venticular Mass and Geometry Following Myocardial Infarction. The Valiant (VALsartan in Acute myocardial iNfarcTion). Echocardiographic Study. J Am Coll Cardiol Img. 2008;1:582-91.
  113. Ghali JK, Tam SW, Sabolinski ML, Taylor AL, Lindenfeld J, Cohn JN, Worcel M. Exploring the Potential Synergistic Action of Spironolactone on Nitric Oxide-Enhancing Therapy:  insights from the African American Heart Trial. J Card Fail. 2008;14(9):718-23.
  114. Ghali, JK. Sex, race and ethnicity: providing quality care for elderly patients hospitalized with heart failure. Aging Health. 2009;5(2):171-176
  115. Anand IS, , Carson P, Gaile E, Song R, Boehmer, Ghali JK, Jaski B, Lindenfeld J, O’Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman AM, DeMets D, Bristow MR. Cardiac Resynchronization Therapy Reduces the Risk of Hospitalizations in Patients With Advanced Heart Failure. Results From the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Trial. Circulation.2009;119:969-977.
  116. Meris A, Amigoni M, Uno H, Thune JJ, Verma A, Kober L, Bourgoun M, McMurray JJ, Velazquez EJ, Maggioni AP, Ghali J, Arnold JMO, Zelenkofske S, Pfeffer MA, Solomon SD. Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. Eur Heart J. 2009;30(1):56-65.
  117. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Venkitachalam L, Ofili E, Yancy C, Feldman AM, Ghali JK, Taylor AL, Cohn JN, Worcel M. Endothelial Nitric Oxide Synthase (NOS3) Polymorphisms in African Americans With Heart Failure: Results From the A-HeFT Trial. J Cardiac Fail 2009;15:191-198.
  118. Adams KF Jr, Patterson JH, Oren RM, Mehra MR, O’Connor CM, Piña IL, Miller AB, Chiong JR, Dunlap SH, Cotts WG, Felker GM, Schocken DD, Schwartz TS, Ghali JK, STAMINA-HFP Registry Investigations. Prospective assessment of the occurrence of anemia in patients with heart failure:  results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. Am Heart J. 2009;157(5)926-32.
  119. Ghali JK, Wikstrand J, Van Veldhuisen DJ, Fagerberg B, Goldstein S, Hjalmarson A, Johansson P, Kjekshus J, Ohlsson L, Samuelsson O, Waagstein F, Wedel H; MERIT-HF Study Group. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). J Card Fail.2009;15(4):310-8.
  120. Ghali JK, Anemia and heart failure. Curr Opin Cardiol. 2009;24:172-178.
  121. Ghali JK, Hamad B, Yasothan U, Kirkpatrick P. Tolvaptan. Nature Reviews Drug Discovery. 2009;8:611-612.
  122. Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD. Conivaptan and its role in the    treatment of hyponatremia. Drug Design, Development and Therapy. 2009;3:253-26
  123. Klapholz M, Abraham WT, Ghali JK, Ponikowski P, Anker SD, Knusel B, Sun Y, Wasserman SM, van Veldhuisen DJ. The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. Eur J Heart Fail. 2009;11(11):1071-7, doi:10.1093/eurjhf/hfp130-133.
  124. Carson P, Tam SW, Ghali JK, Archambault WT, Taylor A, Cohn JN, Braman VM, Worcel M, Anand IS. Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial. JCard Fail 2009;15(10):835-842. 
  125. Adams KF, Piña IL, Ghali JK, Wagoner LE, Dunlap SH, Schwartz TA, Stough WG, Mehra MR, Felker GM, Chiong JR, Patterson JH, Kim J, Butler J, Oren RM. Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. Am Heart J. 2009;158:965-971.
  126. Bachour K, Zmily H, Kizilbash M, Awad K, Hourani R, Hammad H, Sobel JD, Ghali JK, Levine D, Afonso L. Valvular perforation in left-sided native valve infective endocarditis. Clin Cardiol 2009;32(12):E55-62.
  127. Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure: HF-ACTION Randomized Controlled Trial. HF-ACTION Investigators. JAMA 2009;301(14):1439-50.
  128. Levy PD, Nandyal D, Welch RD, Sun JL, Pieper K, Ghali JK, Fonarow GC, Gheorgiade M, O’Connor CM. Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2010;159(2):222-230.e2.
  129. Shin SH, Hung CL, Uno H, Hassanein AH, Verma A, Bourgoun M, Kabel L, Ghali JK, Velazquez EJ, Califf RM, Pfeffer MA, Solomon SD, for the Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure or both. Circulation 2010;121:1096-1103.
  130. Allen LA, Felker GH, Mehra MR, Chiong JR, Dunlap SH, Ghali JK, Lenihan DJ, Oren RM, Wagoner LE, Schwartz TA, Adams KF Jr. Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail. 2010;16(3):230-8.
  131. Ghali JK, Tam SW. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.  J Cardiac Fail 2010;16:419-431.
  132. Levine TB, Giles T, Radzik D, Ghali JK. Effect of dronedarone on exercise capacity and cardiac function in patients with severe left ventricular dysfunction and compensated stable heart failure. Cardiovasc Drugs Ther. 2010 Jul 21. PMID: 20652627. 
  133. Ghali JK, Zmily HD, Farah JO, Daifallah S. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential treatment of hyponatremia. IDrugs 2010;13(11):782-92.
  134. Wu AH, Ghali JK, Neuberg GW, O’Connor CM, Carson PE, Levy WC. Uric acid level and allopurinol use as risk markers or mortality and morbidity in systolic heart failure. Am Heart J 2010;160(5):928-33.
  135. Adams KF Jr, Mehra MR, Oren RM, O’Connor CM, Chiong JR, Ghali JK, Lenihan DJ, Dunlap SH, Patterson JH, Schwartz TA, Felker GM. Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure. Am Heart J. 2010;160(6):1142-8.
  136. Ghali JK, Massie BM, Mann DL, Rich MW. Heart failure guidelines, performance measures, and the practice of medicine: mind the gap. J Am Coll Cardiol 2010;56(25):2077-80.
  137. Ghali JK, Massie BM, Mann DL, Rich MW. Guidelines, performance measures, and the practice of medicine: mind the gap. J Card Fail 2010;16(12):915-8.
  138. Zalawadiya SK, Zmily H, Farah J, Daifallah S, Ali O, Ghali JK. Red cell distribution width and mortality in predominantly African American population with decompensated heart failure. J Cardiac Fail 2011;17:292-298.
  139. Ghali JK, Massie BM, Mann DL, Rich MW. Guidelines are merely guidelines.J Card Fail2011;17:30:208-9.
  140. Daifallah S, Zmily HD, Alqwasmi AH, Zayed H, Ghali JK. Lixivaptan. Drugs of the Future 2011;36(5);351-63.
  141. Zmily HD, Daifallah S, Ghali JK. The potential role for lixivaptan in heart failure and in hyponatremia. Expert Opin Investig Drugs. 2011;20(6):831-48.
  142. Zmily HD, Daifallah S, Ghali JK. Tolvaptan, hyponatremia, and heart failure. Int J Nephrol Renovasc 2011;4:57-51.
  143. Shah AM, Hung CL, Shin SH, Skali H, Verma A, Ghali JK, Kober L, Velazquez EJ, Rouleau JL, McMurry JJV< Pfeffer MA, Solomon SD. Cardiac structure and function, remodeling and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. Am Heart J 2011;162:685-91.
  144. Zalawadiya SK, Veeranna V, Panaich SS, Afonso L, Ghali JK. Gender and ethnic differences in red cell distribution width and its association with mortality among low risk healthyUnited States adults. Am J Cardiol 2012;109(11):1664-70.
  145. Ghali JK, Orlandi C, Abraham WT, for the CK-LX2401. The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study.  Eur J Heart Fail 2012;14(6):642-51.
  146. Taylor AL, Sabolinski ML, Tam SW, Ziesche S, Ghali JK, Archambaut WT, Worcel M, Cohn JN for the A-HEFT Investigators. Effect of fixed-dose combined Isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial. J Cardiac Fail 2012;18:600-06.
  147. Arora NP, Ghali JK. Iron deficiency anemia in heart failure. Heart Fail Rev. 2012 Sep 5.
  148. Storrow AB, Lindsell CJ, Collins SP, Diercks DB, Fillippatos GS, Hiestand BC, Hollander JE, Kirk JD, Levy PD, Miller CD, Naftilan AJ, Nowak RM, Pang PS, Peacock WF, Gheorghiade M, Cleland JG, Gheorghiade M, Abraham WT, Amsterdam EA, Cleland JG, Diercks DB, Dunlap S, Ghali J, Hobbs R, Hiestand BC, Hollander JE, Douglas KJ, Kremastinos D, Levy PD, Lindsell CJ, McCord J, Miller CD, Naftilan AJ, Pang PS, Frank Peacock W, Storrow AB, Trohan V. Standardized reporting criteria for studies evaluating suspected acute heart failure syndromes in the emergency department. J Am Coll Cardiol 2012;60(9):822-32.
  149. Wu AH, Levy WC, Welch KB, Neuberg GW, O’Connor CM, Carson PE, Miller AB, Ghali JK. Association between bilirubin and mode of death in severe systolic heart failure. Am J Cardiol. 2013 Jan 23.
  150. Zmily HD, Alani A, Ghali JK. Evaluation of lixivaptan in euvolemic and hypervolemic hyponatremia and heart failure treatment. Expert Opin Drug Metab Toxicol. 2013;9(5):645-55.
  151. Arora NP, Ghali JK. Anemia and iron deficiency in heart failure. Heart Fail Clin. 2014;10(2):281-294.
  152. Adams KF Jr, Ghali JK, Patterson JH, Stough WG, Butler J, Bauman JL, Ventura HO, Sabbah H, Mackowiak JI, van Veldhuisen DJ. A perspective on re-evaluating digoxin’s role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile. Eur J Heart Fail. 2014 doi:10.1002/ejhf.64.
  153. Patel RC, Goyal H, Shal Al, Ghali JK. Wearing the mask of ST-elevation myocardial infarction: postpericardiotomy syndrome. Am J Emerg Med. 2015 Feb 2. [Epub ahead of print]
  154. Whellan DJ, Kraus WE, Kitzman DW, Rooney B, Keteyian SJ, Pina IL, Ellis SJ, Ghali JK, Lee KL, Cooper LS, O’Connor CM.  Authorship in a multicenter clinical trial: The Heart Failure-A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) Authorship and Publication (HAP) scoring system results.  Am Heart J. 2015;169(4):457-463.e6.


Heart Health Journal Flyer